Even if tyrosinase expression in the peripheral blood of melanoma patients has been widely reported in the literature, only a few papers have been specifically addressed to the evaluation of tyrosinase expression both at diagnosis and during the follow-up of stage III disease-free patients. This evidence concerns the gene TYR and melanoma.